Curative effect and application value of monosialotetrahexosyl ganglioside sodium in patients with vascular Parkinsonism
Objective To investigate the curative effect and application value of monosialotetrahexosyl ganglioside sodium(MGS)combined with Levodopa and Benserazide hydrochlo-ride in the patients with vascular Parkinsonism(VP).Methods A retrospective study was conducted in 80 VP patients were divided into the control group(levodopa and benserazide hydrochlo-ride therapy)and the observation group(MGS combined with Levodopa and Benserazide Hydrochlo-ride therapy)according to the treatment plan,with 40 patients in each group.The clinical efficacy of the two groups was compared,as well as the scores of the second and third scales of the Parkinson's disease rating scale(UPDRS Ⅱ,UPDRS Ⅲ),the Parkinson's disease quality of life questionnaire(PDQ-39).The levels of serum neurofilament light chain(sNFL),β-amyloid precursor protein(β-APP),serotonin(5-HT),apolipoprotein A1,interleukin-32(IL-32),homocysteine(Hcy),interleukin-1(IL-1)before and after treatment were compared betwween the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group,with a statistically significant difference(90.00％vs.67.50％,P<0.05).Compared with the control group,the scores of UPDRS Ⅱ,UPDRS Ⅲ,and PDQ-39 in the observation group were significantly decreased after treatment(P<0.05).Compared with the control group,the levels of serum sNFL,IL-32,Hcy,and IL-1 were significantly decreased after treatment in the observation group,while the levels of serum β-APP,5-HT,and apolipoprotein A1 were significantly increased after treatment in the observation group(P<0.05).Conclusion The efficacy of MGS combined with Levodopa and Benserazide hydrochlo-ride in the treatment of VP patients is confirmed,which improves the motor function,enhances the quality of life,corrects the neurotransmitter disorders,and inhibits the inflammatory reactions.
vascular Parkinsonismlevodopa and benserazide hydrochlo-ridemonosialotetrahexosyl ganglioside sodiuminflammatory factors
万方数据
维普
